Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
- Conditions
- Colorectal CancerQuality of Life
- Registration Number
- NCT00079066
- Lead Sponsor
- NCIC Clinical Trials Group
- Brief Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can target tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Best supportive care is the use of drugs and other treatments to improve the quality of life of patients. Combining cetuximab with best supportive care may slow the growth of the tumor and help patients live longer and more comfortably. It is not yet known whether cetuximab combined with best supportive care is more effective than best supportive care alone in treating metastatic epidermal growth factor receptor-positive colorectal cancer.
PURPOSE: This randomized phase III trial is studying cetuximab and best supportive care to see how well they work compared to best supportive care alone in treating patients with metastatic epidermal growth factor receptor-positive colorectal cancer.
- Detailed Description
OBJECTIVES:
Primary
* Compare survival of patients with metastatic epidermal growth factor receptor-positive colorectal cancer treated with cetuximab and best supportive care vs best supportive care alone.
Secondary
* Compare the time to disease progression in patients treated with these regimens.
* Compare the objective response rate in patients treated with these regimens.
* Compare the quality of life of patients treated with these regimens.
* Compare the health utilities of patients treated with these regimens.
* Conduct a comparative economic evaluation in patients treated with these regimens.
* Determine the safety profile of cetuximab in these patients.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to participating center and ECOG performance status (0 or 1 vs 2). Patients are randomized to 1 of 2 treatment arms.
* Arm I: Patients receive an initial loading dose of cetuximab IV over 120 minutes on day 1. Patients continue to receive maintenance infusions of cetuximab IV over 60 minutes weekly. Patients also receive best supportive care, defined as measures designed to provide palliation of symptoms and improve quality of life as much as possible.
* Arm II: Patients receive best supportive care as in arm I. In both arms, treatment continues in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, and then at 4, 8, 16, and 24 weeks (or until deterioration to ECOG PS 4 or hospitalization for end-of-life care).
Patients are followed every 4 weeks.
PROJECTED ACCRUAL: A total of 500 patients (250 per treatment arm) will be accrued for this study within 20 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 572
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method Safety profile Quality of life by European Organization for Research of the Treatment of Cancer Quality of Life Questionnaire -C30 (EORTC QLQ-C30) Objective response rate Time to progression Health utilities by Health Utilities Index 13 (HU 13) Economic evaluation
Trial Locations
- Locations (33)
Hopital Charles Lemoyne
🇨🇦Greenfield Park, Quebec, Canada
Newfoundland Cancer Treatment and Research Foundation
🇨🇦St. Johns, Newfoundland and Labrador, Canada
Hopital Du Sacre-Coeur de Montreal
🇨🇦Montreal, Quebec, Canada
Cross Cancer Institute at University of Alberta
🇨🇦Edmonton, Alberta, Canada
British Columbia Cancer Agency - Vancouver Island Cancer Centre
🇨🇦Victoria, British Columbia, Canada
Allan Blair Cancer Centre at Pasqua Hospital
🇨🇦Regina, Saskatchewan, Canada
Fraser Valley Cancer Centre at British Columbia Cancer Agency
🇨🇦Surrey, British Columbia, Canada
Saskatoon Cancer Centre at the University of Saskatchewan
🇨🇦Saskatoon, Saskatchewan, Canada
British Columbia Cancer Agency - Vancouver Cancer Centre
🇨🇦Vancouver, British Columbia, Canada
British Columbia Cancer Agency - Centre for the Southern Interior
🇨🇦Kelowna, British Columbia, Canada
NHMRC Clinical Trials Centre
🇦🇺Camperdown, New South Wales, Australia
Saint John Regional Hospital
🇨🇦Saint John, New Brunswick, Canada
Grand River Regional Cancer Centre at Grand River Hospital
🇨🇦Kitchener, Ontario, Canada
Ottawa Hospital Regional Cancer Centre - General Campus
🇨🇦Ottawa, Ontario, Canada
Cancer Centre of Southeastern Ontario at Kingston General Hospital
🇨🇦Kingston, Ontario, Canada
Belleville General Hospital
🇨🇦Belleville, Ontario, Canada
Northwestern Ontario Regional Cancer Care at Thunder Bay Regional Health Sciences Centre
🇨🇦Thunder Bay, Ontario, Canada
Hotel Dieu Health Sciences Hospital - Niagara
🇨🇦St. Catharines, Ontario, Canada
Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre
🇨🇦Toronto, Ontario, Canada
Toronto East General Hospital
🇨🇦Toronto, Ontario, Canada
St. Michael's Hospital - Toronto
🇨🇦Toronto, Ontario, Canada
Mount Sinai Hospital - Toronto
🇨🇦Toronto, Ontario, Canada
St. Joseph's Health Centre - Toronto
🇨🇦Toronto, Ontario, Canada
Prince Edward Island Cancer Centre at Queen Elizabeth Hospital
🇨🇦Charlottetown, Prince Edward Island, Canada
Princess Margaret Hospital
🇨🇦Toronto, Ontario, Canada
Windsor Regional Cancer Centre at Windsor Regional Hospital
🇨🇦Windsor, Ontario, Canada
Centre Hospitalier de l'Universite de Montreal
🇨🇦Montreal, Quebec, Canada
McGill Cancer Centre at McGill University
🇨🇦Montreal, Quebec, Canada
CancerCare Manitoba
🇨🇦Winnipeg, Manitoba, Canada
Nova Scotia Cancer Centre at Queen Elizabeth II Health Sciences Centre
🇨🇦Halifax, Nova Scotia, Canada
Moncton Hospital
🇨🇦Moncton, New Brunswick, Canada
London Regional Cancer Program at London Health Sciences Centre
🇨🇦London, Ontario, Canada
R. S. McLaughlin Durham Regional Cancer Centre at Lakeridge Health Oshawa
🇨🇦Oshawa, Ontario, Canada